Unknown

Dataset Information

0

Emerging agents and regimens for multiple myeloma.


ABSTRACT: The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody-drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.

SUBMITTER: Yang Y 

PROVIDER: S-EPMC7654052 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Emerging agents and regimens for multiple myeloma.

Yang Yang Y   Li Yi Y   Gu Huiyao H   Dong Mengmeng M   Cai Zhen Z  

Journal of hematology & oncology 20201109 1


The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and no  ...[more]

Similar Datasets

| S-EPMC7989091 | biostudies-literature
| S-EPMC6815423 | biostudies-literature
| S-EPMC3183751 | biostudies-other
| S-EPMC6589825 | biostudies-literature
| S-EPMC4114494 | biostudies-literature
| S-EPMC8161993 | biostudies-literature
| S-EPMC9454959 | biostudies-literature
| S-EPMC4131914 | biostudies-literature
| S-EPMC5810847 | biostudies-literature
| S-EPMC3948661 | biostudies-literature